Representative Anthony Brindisi

Representing the 22nd District of New York

Bicameral and Bipartisan Group of Members Join Brindisi to Push for More Transparency in Prescription Drug Pricing

Share

July 8, 2019
Press Release

Congressman Anthony Brindisi (NY-22) joined the Problem Solvers Caucus, a group of Republican and Democrats from the House and Senate, to call for lower prescription drug prices. Brindisi and his colleagues outlined principles for legislation that emphasized transparency and competition.

“No one should have to choose between putting food on their table and pay for the life-saving medication they need,” Brindisi said. “I’ve heard countless stories from Upstate New Yorkers who are paying too much for their prescriptions. This issue has support from Democrats, Republicans, and the President: we need to do more to bring down the cost of prescription drugs.”

Earlier this month, Politico reported prescription drug prices jumped an average of 10.5 percent during the first six months of 2019. Brindisi is doubling down on his calls for increased transparency and competition in the marketplace.

Brindisi continues to lead the charge to lower prescription drug costs in Congress. Earlier this year, Brindisi worked with Republican Congressman John Joyce (PA-13) to introduce the Ensuring Timely Access to Generics Act (H.R. 2455), a bipartisan bill to crack down on tactics used by pharmaceutical companies to delay generic drugs from coming to market. Brindisi’s legislation would give the Food and Drug Administration the ability to deny petitions if the primary purpose of the petition is to delay the drug’s transition to the generic marketplace.

In May, Brindisi held prescription drug roundtables in Utica and Binghamton. He heard stories from constituents about the rising cost of prescription drugs and ideas on how to bring those costs down.

The principles outlined during the press conference are:

  • We support access to medications for patients through more transparency, competition, and affordability in the U.S. prescription drug market.
  • We support price transparency standards that give patients, health care providers, and the federal government clear information about drug costs.
  • We believe drug manufacturers should have to disclose, in a way consumers and providers can understand, the price of treatment for advertised drugs and explanation of prices. 
  • We believe pharmacy benefit managers should have to disclose, in a way consumers and providers can understand, the discounts they receive from drug manufacturers that impact the cost of medications for patients.
  • We support patent transparency standards that help new drugs come to market as soon as possible.
  • We support competition among drug manufacturers that ensures continued R&D, makes drugs more affordable, and increases access for patients who need them. 
  • We believe in enforcement mechanisms that pave the way for new, more affordable drugs if other manufacturers do not comply with transparency standards or engage in anti-competitive behavior.

A photo from the press conference can be found HERE.